-->

Company Registry

AbaStar MDx Inc
Profile last edited on: 2/19/2014

NO Business Identifier is currently available for this company.
Year Founded
2007
First SBIR Year
2010
Latest SBIR Award
2010
Program Status
Inactive

WikiProfile

Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

190 Margate Suite B
Lake Bluff, IL 60044
   (847) 778-0522
   info@abastarmdx.com
   www.abastarmdx.com
Multiple Locations:   
Congressional District:   10
County:   Lake

Public Profile

AbaStar MDx™ Inc. develops blood-based gene expression, molecular diagnostic tests for the accurate diagnosis of mental disorders and neurodegenerative diseases. From a simple blood sample, the Company's gene expression products detect and measure the unique disease-specific gene profile or molecular signature. Determining the molecular signature of a disease from a sample of blood revolutionizes diagnostic technology. For brain disorders, this breakthrough technology enables accurate diagnosis with a laboratory test for the first time. The resultant early detection, patient monitoring, disease progression and effective treatment of these diseases will eliminate years of suffering through misdiagnoses and expensive trial and error medication treatments.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
1-4
Revenue Range
Less than .5M
VC funded?
No
Public/Private
Privately Held
Stock Info
---
IP Holdings
N/A

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount Project Title
1 NIH $200,000
Gene Expression Exon Array Biomarkers To Diagnose Schizophrenia

Key People / Management

  Terry W Osborn --

  Virginia Hanson Paul -- Co-Founder & Vice PresidentBusiness Development

  Marquis P Vawter -- Co-Founder -

SBIR firms in the news

There are no news available.